C.R. Bard, Inc. CEO William Longfield talks to The Wall Street Transcript.

NEW YORK--(BUSINESS WIRE)--Dec. 23, 1998--The Wall Street Transcript has published an in-depth interview with William H. Longfield of C. R. Bard, Inc. (NYSE:BCR), in which he talks at length about his company's future.

He says, "Bard is a 90-year-old company. We achieved our reputation based upon our urological franchise, which is still one of the mainstays of our business. Today we are primarily in the urological, oncology, and peripheral vascular businesses, plus we have a very strong surgical specialties franchise. This past year we sold off our coronary vascular business. In those segments that are left, we're the market leader in most categories."

He explains, "We also have a product for the treatment of GERD. This is a whole new therapy for treating reflux disease, and the clinical studies so far on that product look excellent. We're also in clinical trials on a carotid stent. So we have a number of new therapies we're working on and if just one of those hits, they could substantially change the growth profile of the company."

Looking forward, he states, "We think we can grow our revenue at least in the 8 to 10% range. We believe we can certainly grow at least 15% a year in net income. And we believe we can be the market leader in all the markets that we participate in."

To read the complete interview, go to http://www.twst.com/pdf/bcr.pdf. It requires Adobe Acrobat (tm) reader to view the document. The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations.

The Wall Street Transcript is a premier weekly investment publication serving serious long-term investors for over 35 years. The Transcript publishes industry roundtables and interviews with Wall Street analysts, money managers, and Company CEOs, and is read by top money managers, brokers, and individual investors. For subscription information call (800) 246 -7673.